Possible Founder Effect of the CDKN2A c.146T>C Variant in the Mexican Population: Phenotypic Characterization
Authors:
- María Lourdes Garza-RodríguezMGMaría Lourdes Garza-Rodríguez
- Eren Adrián Alejandro Vargas-MárquezEVEren Adrián Alejandro Vargas-Márquez
- Dione AguilarDADione Aguilar
- Samantha Trujillo-BorniosSTSamantha Trujillo-Bornios
- Hugo Leonid Gallardo-BlancoHugo Leonid Gallardo-Blanco
- Oscar Vidal-GutiérrezOVOscar Vidal-Gutiérrez
- Diana Cristina Pérez-IbaveDiana Cristina Pérez-Ibave
- Carlos Horacio Burciaga-FloresCarlos Horacio Burciaga-Flores
Open Access
Abstract
Background: Germline CDKN2A variants are associated with Familial Atypical Mole-Malignant Melanoma (FAMMM) syndrome. This syndrome involves an increased risk of melanoma, pancreatic cancer, and, in specific populations, duodenal cancer, breast cancer, and astrocytoma. The CDKN2A (c.146T>C) variant has been found in hereditary cancer patients within the Mexican population. Furthermore, the phenotype linked to this variant in Mexico differs from that observed in other groups. This study aims to evaluate the founder effect of the CDKN2A (c.146T>C) variant through epidemiological analysis and to describe the phenotype within our population. Patients and Methods: We examined 72 Mexican patients (14 probands from distinct families, 48 relatives, and 10 nonrelated probands) carrying the CDKN2A (c.146T>C) form three hereditary cancer centers between September 2023 and September 2025. Results: Of the 72 individuals analyzed, 52 (72.22%) tested positive. A cancer diagnosis was established in 27 (37.50%) of the individuals analyzed. Breast cancer was the most common neoplasia, accounting for 19 cases (70.37%), followed by melanoma with 4 cases (14.81%) and ovarian cancer with 2 cases (7.40%). Three patients (11.11%) had two distinct primary neoplasms. Conclusions: Based on our findings and the fact that this variant has been reported nearly exclusively in the Mexican population, we conclude that it has a founder effect in this population. Additionally, the phenotype associated with this variant can vary among populations, with breast cancer being the most common carcinoma rather than melanoma among Mexican carriers, highlighting the importance of updating screening guidelines.Keywords
Funding Information
- Oncology Service of CUCC
This publication has 24 references indexed in Scilit:
- O06: Penetrance and prevalence of CDKN2A pathogenic variants in a large institutional cohort: Scrutinizing the common p.Ile49Thr variantGenetics in Medicine Open, 2024
- Germline mutations in pediatric cancer cohort with mixed‐ancestry MexicansMolecular Genetics & Genomic Medicine, 2023
- Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer riskNature Genetics, 2023
- Hereditary pancreatic cancerInternational Journal of Clinical Oncology, 2021
- CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysisBreast Cancer, 2018
- Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanomaGenetics in Medicine, 2016
- A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessmentGenetics in Medicine, 2015
- Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanomaCancer Epidemiology, 2011
- Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counselingEuropean Journal of Human Genetics, 2010
- Predicting functional significance of cancer-associated p16INK4a mutations in CDKN2AHuman Mutation, 2010